<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/outlook-therapeutics-inc-logo-1200x675.PNG/query-dj0yMDIwMTEyNDEyMTMzOQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/outlook-therapeutics-inc-logo-1200x675.PNG/query-dj0yMDIwMTEyNDEyMTMzOQ"/></p>
<p>Outlook Therapeutics, Inc.（NASDAQ：OTLK）的股票获得了 8 家研究公司的一致&#34;中等买入&#34;推荐，Marketbeat Ratings 报告。一位研究分析师给出了持有建议，另外七位对该公司发出了买入建议。过去一年内对该股票发布报告的分析师中，平均 1 年价格目标为 46.43 美元。</p>
<p>获取 <strong>Outlook Therapeutics</strong> 警报：</p>
<p>OTLK 最近成为多份研究报告的主题。Chardan Capital 将 Outlook Therapeutics 的评级从&#34;中性&#34;调高至&#34;买入&#34;，并设定了 60.00 美元的股价目标。BTIG Research 将 Outlook Therapeutics 的评级从&#34;中性&#34;调高至&#34;买入&#34;，并设定了 50.00 美元的股价目标。HC Wainwright 重申了&#34;买入&#34;评级，并设定了 30.00 美元的股价目标。最后，Capital One Financial 在一份报告中重申了对 Outlook Therapeutics 的&#34;超配&#34;评级。</p>
<p>查看我们对 Outlook Therapeutics 的最新股票报告</p>
<h2>对 Outlook Therapeutics 的对冲基金观点</h2>
<p>一家对冲基金最近增加了其在 Outlook Therapeutics 股票中的持股。根据最新提交给证券交易委员会的 13F 文件，Scotia Capital Inc.在第三季度将其在 Outlook Therapeutics, Inc.（NASDAQ：OTLK）的持股增加了 420.9%。该基金在该季度购入了额外的 273,463 股，持有 338,439 股公司股票。截至最新的 SEC 提交，Scotia Capital Inc.拥有 Outlook Therapeutics 价值 75000 美元的股份，占公司股份的 0.13%。11.20% 的股份由机构投资者持有。</p>
<h2>Outlook Therapeutics 股票表现</h2>
<p>OTLK 周五开盘价为 7.07 美元。股票的 50 天简单移动平均线为 8.50 美元，200 天简单移动平均线为 8.33 美元。该股票的市值为 1.6551 亿美元，市盈率为-0.62，β系数为 0.28。Outlook Therapeutics 的 52 周最低价为 4.00 美元，52 周最高价为 40.60 美元。</p>
<h2>关于 Outlook Therapeutics（获取免费报告</h2>
<p>Outlook Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于开发和商业化用于各种眼科适应症的单克隆抗体。其主要产品候选药物是 ONS-5010，一种含有贝伐单抗的眼科制剂，目前正在进行湿性年龄相关性黄斑变性和其他视网膜疾病的 III 期临床试验。</p>
<h2>参见</h2>
<ul>
<li>我们喜欢的五支股票胜过 Outlook Therapeutics</li>
<li>什么是热门股票？热门股票解释</li>
<li>MarketBeat 周回顾-5/27-5/31</li>
<li>股息捕捉策略：你需要了解的</li>
<li>Foot Locker 的季度报告让怀疑者四处奔跑</li>
<li>什么是 WallStreetBets 以及他们瞄准的股票？</li>
<li>Costco Wholesale 可以创下新高；反弹即将到来</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1RMSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1RMSw"/></p>
<p><em>此即时新闻警报由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 这家军方支持的股票 “拥有” 人工智能市场（来自 Porter &amp; Company）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDA2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDA2"/></p>
<h2>现在是否值得投资 1000 美元购买 Outlook Therapeutics 股票？</h2>
<p>在考虑购买 Outlook Therapeutics 股票之前，您会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Outlook Therapeutics 并不在名单上。</p>
<p>尽管 Outlook Therapeutics 目前在分析师中有&#34;中等买入&#34;评级，但顶级分析师认为这五支股票更值得购买。</p>
<p>查看这五支股票</p>

塔吉特

OTLK

<p>Outlook Therapeutics, Inc.（纳斯达克股票代码：OTLK）获得了分析师们的 “中等买入” 一致评级。该股票的 1 年价格目标为 46.43 美元，并获得了七位分析师的买入推荐。该公司专注于开发和商业化用于眼科适应症的单克隆抗体。目前该股票的价格为 7.07 美元</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/outlook-therapeutics-inc-logo-1200x675.PNG/query-dj0yMDIwMTEyNDEyMTMzOQ" alt="" original-src="https://www.marketbeat.com/logos/outlook-therapeutics-inc-logo-1200x675.PNG?v=20201124121339"/></p>
<p>Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have earned a consensus recommendation of &#34;Moderate Buy&#34; from the eight research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $46.43.</p>
<div class="lb-trans"><p>Outlook Therapeutics, Inc.（NASDAQ：OTLK）的股票获得了 8 家研究公司的一致&#34;中等买入&#34;推荐，Marketbeat Ratings 报告。一位研究分析师给出了持有建议，另外七位对该公司发出了买入建议。过去一年内对该股票发布报告的分析师中，平均 1 年价格目标为 46.43 美元。</p>
</div><p>Get <strong>Outlook Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Outlook Therapeutics</strong> 警报：</p>
</div><p>OTLK has been the topic of a number of recent research reports. Chardan Capital raised Outlook Therapeutics from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $60.00 price objective on the stock in a report on Thursday, February 15th. BTIG Research raised Outlook Therapeutics from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $50.00 price objective on the stock in a report on Wednesday, March 27th. HC Wainwright reissued a &#34;buy&#34; rating and set a $30.00 price objective on shares of Outlook Therapeutics in a report on Friday, May 17th. Finally, Capital One Financial reissued an &#34;overweight&#34; rating on shares of Outlook Therapeutics in a report on Friday, February 16th.</p>
<div class="lb-trans"><p>OTLK 最近成为多份研究报告的主题。Chardan Capital 将 Outlook Therapeutics 的评级从&#34;中性&#34;调高至&#34;买入&#34;，并设定了 60.00 美元的股价目标。BTIG Research 将 Outlook Therapeutics 的评级从&#34;中性&#34;调高至&#34;买入&#34;，并设定了 50.00 美元的股价目标。HC Wainwright 重申了&#34;买入&#34;评级，并设定了 30.00 美元的股价目标。最后，Capital One Financial 在一份报告中重申了对 Outlook Therapeutics 的&#34;超配&#34;评级。</p>
</div><p><strong>Check Out Our Latest Stock Report on Outlook Therapeutics</strong></p>
<div class="lb-trans"><p>查看我们对 Outlook Therapeutics 的最新股票报告</p>
</div><h2>Hedge Funds Weigh In On Outlook Therapeutics</h2>
<div class="lb-trans"><h2>对 Outlook Therapeutics 的对冲基金观点</h2>
</div><p>A hedge fund recently raised its stake in Outlook Therapeutics stock. Scotia Capital Inc. grew its position in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) by 420.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 338,439 shares of the company's stock after purchasing an additional 273,463 shares during the quarter. Scotia Capital Inc. owned approximately 0.13% of Outlook Therapeutics worth $75,000 as of its most recent SEC filing. 11.20% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一家对冲基金最近增加了其在 Outlook Therapeutics 股票中的持股。根据最新提交给证券交易委员会的 13F 文件，Scotia Capital Inc.在第三季度将其在 Outlook Therapeutics, Inc.（NASDAQ：OTLK）的持股增加了 420.9%。该基金在该季度购入了额外的 273,463 股，持有 338,439 股公司股票。截至最新的 SEC 提交，Scotia Capital Inc.拥有 Outlook Therapeutics 价值 75000 美元的股份，占公司股份的 0.13%。11.20% 的股份由机构投资者持有。</p>
</div><h2>Outlook Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Outlook Therapeutics 股票表现</h2>
</div><p>Shares of OTLK opened at $7.07 on Friday. The stock's 50-day simple moving average is $8.50 and its 200 day simple moving average is $8.33. The stock has a market capitalization of $165.51 million, a price-to-earnings ratio of -0.62 and a beta of 0.28. Outlook Therapeutics has a 52-week low of $4.00 and a 52-week high of $40.60.</p>
<div class="lb-trans"><p>OTLK 周五开盘价为 7.07 美元。股票的 50 天简单移动平均线为 8.50 美元，200 天简单移动平均线为 8.33 美元。该股票的市值为 1.6551 亿美元，市盈率为-0.62，β系数为 0.28。Outlook Therapeutics 的 52 周最低价为 4.00 美元，52 周最高价为 40.60 美元。</p>
</div><h2>About Outlook Therapeutics (Get Free Report</h2>
<div class="lb-trans"><h2>关于 Outlook Therapeutics（获取免费报告</h2>
</div><p>Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.</p>
<div class="lb-trans"><p>Outlook Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于开发和商业化用于各种眼科适应症的单克隆抗体。其主要产品候选药物是 ONS-5010，一种含有贝伐单抗的眼科制剂，目前正在进行湿性年龄相关性黄斑变性和其他视网膜疾病的 III 期临床试验。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than Outlook Therapeutics</li>
<li>What Are Trending Stocks? Trending Stocks Explained</li>
<li>MarketBeat Week in Review – 5/27 - 5/31</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>Foot Locker’s Quarter Sends Doubters Running</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>Costco Wholesale Can Hit New Highs; A Rebound Is Coming</li>
</ul>
<div class="lb-trans"><h2>参见</h2>
<ul>
<li>我们喜欢的五支股票胜过 Outlook Therapeutics</li>
<li>什么是热门股票？热门股票解释</li>
<li>MarketBeat 周回顾-5/27-5/31</li>
<li>股息捕捉策略：你需要了解的</li>
<li>Foot Locker 的季度报告让怀疑者四处奔跑</li>
<li>什么是 WallStreetBets 以及他们瞄准的股票？</li>
<li>Costco Wholesale 可以创下新高；反弹即将到来</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1RMSw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=OTLK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ This military-backed stock “owns” AI market (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 这家军方支持的股票 “拥有” 人工智能市场（来自 Porter &amp; Company）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MDA2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8006&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Outlook Therapeutics right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1000 美元购买 Outlook Therapeutics 股票？</h2>
</div><p>Before you consider Outlook Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买 Outlook Therapeutics 股票之前，您会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outlook Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Outlook Therapeutics 并不在名单上。</p>
</div><p>While Outlook Therapeutics currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Outlook Therapeutics 目前在分析师中有&#34;中等买入&#34;评级，但顶级分析师认为这五支股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五支股票</p>
</div>

Outlook Therapeutics, Inc.（纳斯达克代码：OTLK）获得分析师的 “适度买入” 平均评级